Muiesan Paolo, Vergani Diego, Mieli-Vergani Giorgina
Institute of Liver Studies, King's College London School of Medicine at King's College Hospital, Denmark Hill, London SE5 9RS, UK.
J Hepatol. 2007 Feb;46(2):340-8. doi: 10.1016/j.jhep.2006.11.006. Epub 2006 Dec 1.
Liver transplantation (LT) is now a standard treatment for children with end-stage liver disease with excellent 1- and 5-year survival. This has been achieved through improvement of surgical techniques and anti-rejection treatment and management. The donor pool for children has been extended by the use of cut-down, split, living-related and, recently, non-heart-beating donor and isolated hepatocyte transplantation. Though the majority of transplanted children enjoy an excellent quality of life, there remain a high number of possible complications, including short-term primary non-function, vascular and biliary problems, bowel perforation, severe rejection, infection, hypertension and long-term renal impairment, chronic rejection, de novo autoimmunity, lymphoproliferative disease and cancer, most of which are related to anti-rejection drug toxicity. Hence, the focus of research for paediatric LT should be induction of tolerance, avoiding long-term immunosuppression and its toxicity.
肝移植(LT)现已成为终末期肝病患儿的标准治疗方法,其1年和5年生存率极佳。这是通过手术技术的改进以及抗排斥治疗与管理实现的。通过采用减体积肝移植、劈离式肝移植、活体亲属供肝移植,以及最近的非心脏跳动供体肝移植和孤立性肝细胞移植,儿童供体库得以扩大。尽管大多数接受移植的儿童生活质量良好,但仍存在大量可能的并发症,包括短期原发性无功能、血管和胆道问题、肠穿孔、严重排斥反应、感染、高血压以及长期肾功能损害、慢性排斥反应、新发自身免疫性疾病、淋巴增殖性疾病和癌症,其中大多数与抗排斥药物毒性有关。因此,小儿肝移植的研究重点应是诱导免疫耐受,避免长期免疫抑制及其毒性。